Herceptin acts as an anti-angiogenic cocktail
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression28,116,117.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [116]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationThrombospondins as matricellular modulators of cell function
Bornstein, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12749 · Cited by 470
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 109
Jain, R. K., & Carmeliet, P. (2001) · Scientific American · doi:10.1038/scientificamerican1201-38 · Cited by 94
Self-citation
Research works printed but not linked: 1
- Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
Cited by
Items 201–300 of 622
Blackwell, K., Dewhirst, M. W., Liotcheva, V. B., Snyder, S. A., Broadwater, G., Bentley, R. C., Lal, A., Riggins, G. J., Anderson, S., Vredenburgh, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0695 · Cited by 69
Hak, S., Reitan, N. K., Haraldseth, O., & Davies, C. D. L. (2010) · Angiogenesis · doi:10.1007/s10456-010-9176-y · Cited by 71
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 68
van der Horst, E. H., Chinn, L., Wang, M., Velilla, T., Tran, H., Madrona, Y., Lam, A., Ji, M., Hoey, T. C., & Sato, A. K. (2009) · Neoplasia · doi:10.1593/neo.81536 · Cited by 62
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Shim, H. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.10.063 · Cited by 78
Fendler, W. P., Lechner, H., Todica, A. S., Paprottka, K. J., Paprottka, P. M., Jakobs, T. F., Michl, M., Bartenstein, P., Lehner, S., & Haug, A. R. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.165050 · Cited by 61
Targeted therapies for the treatment of cancer
Kim, J. A. (2003) · The American Journal of Surgery · doi:10.1016/s0002-9610(03)00212-5 · Cited by 61
Cancer therapeutic antibodies come of age: Targeting minimal residual disease
Ben-Kasus, T., Schechter, B., Sela, M., & Yarden, Y. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.003 · Cited by 59
Du, S. M., Xiong, H., Xu, C., Lu, Y., & Yao, J. (2019) · Biomaterials Science · doi:10.1039/c8bm01350k · Cited by 62
Beckers, J., Herrmann, F., Rieger, S., Drobyshev, A. L., Horsch, M., de Angelis, M. H., & Seliger, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20798 · Cited by 59
Integrating molecular diagnostics into anticancer drug discovery
Peták, I., Schwab, R. E., Őrfi, L., Kopper, L., & Kéri, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3135 · Cited by 61
Alameddine, R. S., Otrock, Z. K., Awada, A. H., & Shamseddine, A. I. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff362 · Cited by 61
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts
Ooyama, A., Oka, T., Zhao, H., Yamamoto, M., Akiyama, S., & Fukushima, M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.008 · Cited by 60
Therapeutic Monoclonal Antibodies
Yamada, T. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.37 · Cited by 78
Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumab
Chen, T., Liu, Z., Zeng, W., & Huang, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-53699-w · Cited by 60
Moreno‐Aspitia, A., & Perez, E. A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.08.005 · Cited by 55
Hicks, D. G., & Kulkarni, S. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-1008-taatfe · Cited by 57
Trastuzumab versus lapatinib: The cardiac side of the story
Azim, H. A., Azim, H. A., & Escudier, B. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.06.007 · Cited by 60
Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice
Jiang, H., Tao, W., Zhang, M., Pan, S., Kanwar, J. R., & Sun, X. (2009) · Cancer Investigation · doi:10.3109/07357900902744510 · Cited by 55
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Maadi, H., Nami, B., Tong, J., Li, G., & Wang, Z. (2018) · BMC Cancer · doi:10.1186/s12885-018-4143-x · Cited by 63
Maharati, A., & Moghbeli, M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04434-7 · Cited by 55
Albini, A., Cesana, E., Donatelli, F., Cammarota, R., Bucci, E., Baravelli, M., Anza', C., & Noonan, D. (2011) · Future Cardiology · doi:10.2217/fca.11.54 · Cited by 47
Syed, A., Whisenant, J. G., Barnes, S. L., Sorace, A. G., & Yankeelov, T. E. (2020) · Cancers · doi:10.3390/cancers12061682 · Cited by 60
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)
Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 55
Trastuzumab in the management of early and advanced stage breast cancer.
Bartsch, R., Wenzel, C., & Steger, G. G. (2007) · PubMed Central · Cited by 64
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
Emde, A., Köstler, W. J., & Yarden, Y. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.09.002 · Cited by 61
Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy
Mpekris, F., Panagi, M., Charalambous, A., Voutouri, C., & Stylianopoulos, T. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101626 · Cited by 78
Kaumaya, P. T. P., & Foy, K. C. (2012) · Future Oncology · doi:10.2217/fon.12.95 · Cited by 55
Metronomic therapy and breast cancer: A systematic review
Montagna, E., Cancello, G., Dellapasqua, S., Munzone, E., & Colleoni, M. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.002 · Cited by 51
Angiogenesis in cutaneous disease: Part I
Nguyen, A., Hoang, V., Laquer, V. T., & Kelly, K. M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.05.052 · Cited by 55
ERBB oncogene proteins as targets for monoclonal antibodies
Polanovsky, O. L., Lebedenko, E. N., & Deyev, S. M. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912030029 · Cited by 51
HER-2-positive metastatic breast cancer: trastuzumab and beyond
Metro, G., Mottolese, M., & Fabi, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2583 · Cited by 53
Gao, D., Gao, J., Xu, M. T., Cao, Z., Zhou, L., Li, Y., Xie, X., Jiang, Q. Y., Wang, W., & Liu, J. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00761 · Cited by 49
Zhang, X., Chen, J., Weng, Z., Li, Q., Zhao, L., Yu, N., Deng, L., Xu, W., Yang, Y., Zhu, Z., et al. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.009 · Cited by 51
Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy
Francia, G., Emmenegger, U., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.011 · Cited by 49
Molecular targeted therapies in breast cancer: Where are we now?
Widakowich, C., de Azambuja, E., Gil, T., Cardoso, F., Dinh, P., Awada, A. H., & Piccart, M. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.015 · Cited by 48
Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.
Levêque, D., Wisniewski, S., & Jehl, F. (2005) · PubMed · Cited by 53
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers
Bajo, A. M., Schally, A. V., Groot, K., & Szepesházi, K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601404 · Cited by 47
Cho, H.-M., Rosenblatt, J. D., Kang, Y., Iruela‐Arispe, M. L., Morrison, S. L., Penichet, M. L., Kwon, Y., Kim, T., Webster, K. A., Nechushtan, H., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0321 · Cited by 46
McCormack, D. R., Walsh, A. J., Sit, W. W., Arteaga, C. L., Chen, J., Cook, R. S., & Skala, M. C. (2014) · Biomedical Optics Express · doi:10.1364/boe.5.002247 · Cited by 49
Emerging trends and therapeutic applications of monoclonal antibodies
Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 51
Moon, H., Han, W., Ahn, S. K., Cho, N., Moon, W. K., Im, S., Park, I. A., & Noh, D. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182686bd9 · Cited by 46
Hang, Q., Isaji, T., Hou, S., Im, S., Fukuda, T., & Gu, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.682229 · Cited by 47
Sorace, A. G., Quarles, C. C., Whisenant, J. G., Hanker, A. B., McIntyre, J. O., Sanchez, V. M., & Yankeelov, T. E. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3680-8 · Cited by 45
Chen, A. Y.-C., Cuevas, I., Kenny, P. A., Miyake, H., Mace, K., Ghajar, C. M., Boudreau, A., Bissell, M. J., & Boudreau, N. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4069 · Cited by 51
Microvascular morphometrics of the hypophysis and pituitary tumors: From bench to operating theatre
Ieva, A. D., Weckman, A. M., Michele, J. D., Rotondo, F., Grizzi, F., Kovács, K., & Cusimano, M. D. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.04.009 · Cited by 46
Maruyama, T., Mimura, K., Izawa, S., Inoue, A., Shiba, S., Watanabe, M., Kawaguchi, Y., Inoue, M., Nogata, H., Inoue, S., et al. (2011) · PubMed · Cited by 43
Barth, A. S., Zhang, Y., Li, T., Smith, R. R., Chimenti, I., Terrovitis, I., Davis, D. R., Kizana, E., Ho, A., O'Rourke, B. P., et al. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0016 · Cited by 44
Chen, J., Huang, K., Chen, Q., Deng, C., Zhang, J., & Zhong, Z. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b15832 · Cited by 45
Ko, N. R., Van, S. Y., Hong, S. H., Kim, S.-Y., Kim, M., Lee, J. S., Lee, S. J., Lee, Y.-K., Kwon, I. K., & Oh, S. J. (2020) · Nanomaterials · doi:10.3390/nano10010091 · Cited by 42
Oldham, M., Sakhalkar, H. S., Oliver, T., Johnson, G. A., & Dewhirst, M. W. (2008) · Journal of Biomedical Optics · doi:10.1117/1.2907968 · Cited by 45
Intra- and extracellular signaling by endothelial neuregulin-1
Iivanainen, E., Paatero, I., Heikkinen, S.-M., Junttila, T. T., Cao, R., Klint, P., Jaakkola, P., Cao, Y., & Elenius, K. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.03.042 · Cited by 50
Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy
Waldmann, T. A., & Morris, J. C. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90003-0 · Cited by 47
E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model.
Zhou, Z., Zhou, R., Guan, H., Bucana, C. D., & Kleinerman, E. S. (2003) · PubMed · Cited by 42
Schiffer, I. B., Gebhard, S., Heimerdinger, C. K., Heling, A., Hast, J., Wollscheid, U., Seliger, B., Tanner, B., Gilbert, S., Beckers, T., et al. (2003) · PubMed · Cited by 48
Singh, R., Kim, W. J., Kim, P.-H., & Hong, H. J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.111 · Cited by 40
Endothelial adhesion molecules in breast cancer invasion into the vascular and lymphatic systems
Dua, R. S., Gui, G. P. H., & Isacke, C. M. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.05.015 · Cited by 41
The ErbB receptors and their role in cancer progression
Holbro, T., Civenni, G., & Hynes, N. E. (2003) · Elsevier eBooks · doi:10.1016/b978-012160281-9/50009-8 · Cited by 45
Dey, M., Baldys, A., Sumter, D. B., Göőz, P., Luttrell, L. M., Raymond, J. R., & Göőz, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168054 · Cited by 40
“Several ErbB family inhibitors, including Herceptin, have been shown to reduce vascular permeability in a mouse model of human breast cancer (Izumi et al., 2002) and EGFR inhibition was shown to decrease vascular permeability in vivo in a lung cancer model (Wu et al.”
BackgroundOvercoming Treatment Resistance in HER2-Positive Breast Cancer: Potential Strategies
Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 45
HER2: An emerging biomarker in non-breast and non-gastric cancers
Omar, N., Yan, B., & Salto‐Tellez, M. (2015) · Pathogenesis · doi:10.1016/j.pathog.2015.05.002 · Cited by 43
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 46
Lange, T., Nentwich, M. F., Lueth, M., Yekebas, E. F., & Schumacher, U. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.04.013 · Cited by 39
Targeted Inhibition of Kinases in Cancer Therapy
Baker, S. J., & Reddy, E. P. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20220 · Cited by 51
Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib
Tomasello, G., Bedard, P. L., de Azambuja, E., Lossignol, D., Devriendt, D., & Piccart, M. J. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.11.003 · Cited by 39
Jarrett, A. M., Bloom, M. J., Godfrey, W. H., Syed, A., Ekrut, D. A., Ehrlich, L. I. R., Yankeelov, T. E., & Sorace, A. G. (2018) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqy014 · Cited by 42
Reichardt, W., Hu‐Lowe, D. D., Torres, D. M., Weissleder, R., & Bogdanov, A. A., Jr. (2005) · Neoplasia · doi:10.1593/neo.05139 · Cited by 41
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
Gelardi, T., Damiano, V., Rosa, R., Bianco, R., Cozzolino, R., Tortora, G., Laccetti, P., D’Alessio, G., & Lorenzo, C. D. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605499 · Cited by 39
Monoclonal antibody therapy for breast cancer: Herceptin
Finn, R. S., & Slamon, D. J. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21010-3 · Cited by 44
New approaches to reverse resistance to hormonal therapy in human breast cancer
Weinberg, O. K., Márquez‐Garbán, D. C., & Pietras, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.06.002 · Cited by 49
Receptor-Targeted Cancer Therapy
Richter, M., & Zhang, H. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.271 · Cited by 47
Goel, S., Fukumura, D., & Jain, R. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203794109 · Cited by 39
Self-citationBiomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand
Kulhari, H., Pooja, D., Rompicharla, S. V. K., Sistla, R., & Adams, D. J. (2015) · Medicinal Research Reviews · doi:10.1002/med.21345 · Cited by 41
de Jonge, M. J. A., Hamberg, P., Verweij, J., Savage, S., Suttle, A. B., Hodge, J. P., Arumugham, T., Pandite, L. N., & Hurwitz, H. I. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9885-8 · Cited by 40
Flaxseed oil–trastuzumab interaction in breast cancer
Mason, J. K., Chen, J., & Thompson, L. U. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.05.052 · Cited by 38
Krämer-Marek, G., Gijsen, M., Kiesewetter, D. O., Bennett, R., Roxanis, I., Zieliński, R., Kong, A. H., & Capala, J. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096685 · Cited by 38
Braman, N. M., Prasanna, P., Bera, K., Alilou, M., Khorrami, M., Leo, P., Etesami, M., Vulchi, M., Turk, P., Gupta, A. B., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4148 · Cited by 41
HER-2-Positive Breast Cancer: Hope Beyond Trastuzumab
Bartsch, R., Wenzel, C., Zielinski, C. C., & Steger, G. G. (2007) · BioDrugs · doi:10.2165/00063030-200721020-00001 · Cited by 42
The potential legacy of cancer nanotechnology: cellular selection
Patra, H. K., & Turner, A. P. F. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.10.004 · Cited by 35
Targeting Tumors with Small Molecule Peptides
Cheetham, A. G., Keith, D., Zhang, P., Lin, R., Su, H., & Cui, H. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151130214646 · Cited by 41
Song, Y., Zhao, X., Song, K., & Shang, Z.-J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074464 · Cited by 40
HER2-positive male breast cancer: an update
Ottini, L., Ottini, L., Capalbo, C., Rizzolo, P., Silvestri, V., Rizzo, & Russo (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6519 · Cited by 47
Bilateral macular ischemia and severe visual loss following trastuzumab therapy
Saleh, M., Bourcier, T., Noël, G., Speeg‐Schatz, C., & Gaucher, D. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.555781 · Cited by 37
Zhao, H., Ooyama, A., Yamamoto, M., Ikeda, R., Haraguchi, M., Tabata, S., Furukawa, T., Che, X., Iwashita, K., Oka, T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.045 · Cited by 39
Biological markers of invasive breast cancer
Matsumoto, A., Jinno, H., Ando, T., Fujii, T., Nakamura, T., Saito, J., Takahashi, M., Hayashida, T., & Kitagawa, Y. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv153 · Cited by 41
Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Liu, M., Li, Z., Yang, J., Jiang, Y., Chen, Z., Ali, Z., He, N., & Wang, Z. (2016) · Cell Proliferation · doi:10.1111/cpr.12266 · Cited by 42
HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
Pupa, S. M., Tagliabue, E., Ménard, S., & Anichini, A. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20387 · Cited by 39
Maurer, S., Steinbacher, J., Schmiedel, B. J., Kousis, P. C., Steinle, A., Jung, G., Große‐Hovest, L., & Salih, H. R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400872 · Cited by 40
Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells
Xu, Y., Benlimame, N., Su, J., He, Q., & Alaoui‐Jamali, M. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604901 · Cited by 39
Tsang, R. Y., Sadeghi, S., & Finn, R. S. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3783 · Cited by 48
Metronomic chemotherapy for advanced breast cancer patients
Cazzaniga, M. E., Dionísio, M. R., & Riva, F. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.12.019 · Cited by 35
Targeting Her-2/neu in Breast Cancer: As Easy as This!
Azim, H. A., & Azim, H. A. (2008) · Oncology · doi:10.1159/000151362 · Cited by 39
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 41
The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations
Lin, A., & Rugo, H. S. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0008-2 · Cited by 39
Chang, Z., Wei, J., Qin, C.-F., Hao, K., Tian, X., Xie, K., Xie, X., & Yang, Y.-M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2036-4 · Cited by 34
The Inhibitory Effects of Trastuzumab on Corneal Neovascularization
Güler, M., Yılmaz, T., Özercan, İ. H., & Elkıran, E. T. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.09.022 · Cited by 34
Sorace, A. G., Syed, A., Barnes, S. L., Quarles, C. C., Sanchez, V. M., Kang, H., & Yankeelov, T. E. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0994-1 · Cited by 34
Pellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10058-y · Cited by 33
Hamano, S., Mori, Y., Aoyama, M., Kataoka, H., Tanaka, M., Ebi, M., Kubota, E., Mizoshita, T., Tanida, S., Johnston, R. N., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.046 · Cited by 33
Metadata
- Authors
- Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature
- Published
- 2002-03
- Volume
- 416
- Issue
- 6878
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034801324
- Cited by
- 623
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P01CA080124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.